Glenmark launches hair loss treatment in Russia

MUMBAI: Glenmark Pharmaceuticals announced the launch of Nourkrin in Russia, for addressing one of the key underlying causes of hair loss. Nourkrin Woman and Nourkrin Man will be marketed in Russia by Glenmark Impex LLC, the Russian subsidiary of Glenmark Pharmaceuticals, under a licensing agreement with Denmark-headquartered firm Pharma Medico ApS, says a company statement.

Glenmark had already launched Nourkrin Woman in India in early 2018. Nourkrin contains Marilex, a proprietary scientific formula, rich in specific proteoglycans essential for hair follicle growth, the company claims. Nourkrin is a proven formula based on more than 56 scientific studies and is recognized by leading regulatory agencies globally, the statement adds.